188 results on '"Varaldo, R."'
Search Results
2. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive allogeneic haematopoietic stem cell transplant recipients: risk factors and outcome
3. DLI after haploidentical BMT with post-transplant CY
4. Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin’s lymphoma
5. Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update
6. Second haploidentical stem cell transplantation for primary graft failure
7. DISCONTINUING IMMUNOSUPPRESSIVE THERAPY FOLLOWING AN ALLOGENEIC HEMOPOIETIC STEM CELL TRANSPLANT (HSCT):A CROSS SECTIONAL ANALYSIS OF 799 PATIENTS, 1 YEAR POST TRANSPLANT: PH-P337
8. UNMANIPULATED HAPLOIDENTICAL TRANSPLANTS FOR ACUTE MYELOID LEUKEMIA (AML) AND REFRACTORY ANEMIA WITH EXCESS BLASTS (RAEB): PH-O126
9. PRE-ENGRAFTMENT BLOODSTREAM INFECTIONS IN 489 HAEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: AETIOLOGY, RISK FACTORS AND IMPACT ON MORTALITY.: PH-O023
10. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts: a single Center experience in 488 patients: O383
11. Anti-CD26 monoclonal antibody for the treatment of steroidrefractory acute graft-versus-host disease (SR-GvHD): a report of two prospective studies: O159
12. Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse
13. Risk factors for non-relapse mortality in 287 patients receiving 1288 donor lymphocyte infusions: P1046
14. Post-transplant CMV reactivation after CBT: the role of delayed immune reconstitution or donorʼs seronegativity?: P756
15. Intra-bone cord blood transplant is associated with reconstitution of haematopoietic stem cell reservoir in adult patients: P523
16. Myeloablative transplants from unrelated donors: intra-bone cord blood compared to adult unrelated donor; a single-centre experience: O408
17. Acute graft-versus-host disease II-IV in 1465 patients: has outcome improved over the past two decades?: O386
18. Aggressive multiple sclerosis: a single‐centre, real‐world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab
19. Intrabone marrow transplantation of cord blood cells is associated with better platelet recovery and decreased acute GvHD as compared with intravenous transplantation: an EUROCORD matched-paired analysis: O106
20. S1624 A DAY 100 LAB-SCORE PREDICTS EXTENSIVE CGVHD, OVERALL SURVIVAL AND TRANSPLANT-RELATED MORTALITY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: FINAL ANALYSIS
21. PF780 STEM CELL TRANSPLANTATION FOR ACQUIRED APLASTIC ANEMIA: THE ROLE OF THE CONDITIONING REGIMEN
22. Visceral leishmaniasis in hematopoietic cell transplantation: Case report and review of the literature
23. Improved Outcome of alternative donor transplantation in patients with myelofibrosis: From unrelated to haploidentical family donors
24. La complessità della New Economy: Tecnologia e Organizzazione
25. Percorsi di innovazione nei modelli di business
26. I rapporti con il mercato delle medie imprese italiane: risultati di una case study research
27. Un tesoro emergente. Le medie imprese italiane dell'era globale
28. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up (on behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia)
29. Chronicmyeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of thepatients alive after a 6-year follow-up
30. TREATMENT OF PHILADELPHIA-POSITIVE CHRONIC MYELOID LEUKEMIA WITH IMATINIB: THE IMPORTANCE OF A STABLE MOLECULAR RESPONSE
31. Marketing-non-marketing all’italiana. Virtù, limiti e prospettive
32. Chemoimmunotherapy with low dose vinorelbine and interleukin-2 in treatment of patients with metastatic renal cell carcinoma
33. La società italiana di marketing al passaggio del suo primo triennio di vita
34. DLI after haploidentical BMT with post-transplant CY
35. PEG-Intron in essential thrombocythaemia: two years treatment evaluation
36. Pharmacologic characteristics and clinical activity of human rituximab anti-C monoclonal antibody
37. Quality of life and brain function during high dose recombinant human erythropoietin treatment in low-risk myelodysplastic syndromes
38. PEG Intron in essential thrombocythemai: two years tretament in 90 patients
39. Implications for managerial and industrial policy
40. Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin’s lymphoma
41. Peg Interferon a- 2b (Peg Intron) in essential Thrombocythemia
42. Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse
43. Lymphoplasmacytic lymphoma/immunocytoma: towards a disease-targeted treatment?
44. Thalidomide in agnogenic and secondary myelofibrosis
45. Cambiamenti istituzionali nell'impresa distrettuale: meccanismi inerziali e logiche di evoluzione
46. I rapporti con il mercato delle medie imprese italiane: risultati di una case study research
47. Lineapiù: oltre le frontiere imprenditoriali del distretto
48. THE EVOLUTIONARY NATURA OF THE FIRMS WITHIN INDUSTRIAL DISTRICTS
49. L’industrialismo nel pensiero di Antonio Renzi
50. Franchising e internazionalizzazione delle imprese
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.